Home » Topics » Regulatory » EMA

EMA
RSS

Positive CHMP opinion on new indications for Xarelto

Sep. 27, 2011

No Comments

Gilead Sciences announces CHMP's opinion on Eviplera

Sep. 27, 2011

No Comments

Optimer Pharmaceuticals and Astellas gain CHMP recommendation for Dificid approval

Sep. 26, 2011

No Comments

Rasitrio recommended for approval in E.U.

Sep. 26, 2011

No Comments

CHMP issues opinion on Edarbi for essential hypertension

Sep. 26, 2011

No Comments

EMA begins review of orlistat-containing antiobesity medicines

Sep. 26, 2011

No Comments

EMA confirms positive benefit-to-risk balance for Multaq

Sep. 23, 2011

No Comments

EMA committee recommends extending approval of Levemir

Sep. 23, 2011

No Comments

Mesoblast clear to initiate phase II trial of Revascor

Sep. 5, 2011

No Comments

EP-217609 obtains European orphan drug status

Aug. 24, 2011

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

EMA
RSS

Positive CHMP opinion on new indications for Xarelto

Gilead Sciences announces CHMP's opinion on Eviplera

Optimer Pharmaceuticals and Astellas gain CHMP recommendation for Dificid approval

Rasitrio recommended for approval in E.U.

CHMP issues opinion on Edarbi for essential hypertension

EMA begins review of orlistat-containing antiobesity medicines

EMA confirms positive benefit-to-risk balance for Multaq

EMA committee recommends extending approval of Levemir

Mesoblast clear to initiate phase II trial of Revascor

EP-217609 obtains European orphan drug status

Today's news in brief

Today's news in brief

In muscular dystrophies, gene therapies race the clock

Bridgebio, with FDA approval, faces Pfizer in ATTR

Phase III AMD miss leaves BLA Outlook same with bevacizumab

EMA RSS

EMA
RSS